A case of Birt-Hogg-Dubé syndrome implying reduced or no wild-type folliculin without mutated protein is pathogenic
Introduction
Birt-Hogg-Dubé syndrome (BHDS) is an autosomal dominantly-inherited syndrome caused by a germline mutation of the folliculin (FLCN) gene and is characterized by cutaneous fibrofolliculomas, renal tumors, and multiple lung cysts with or without spontaneous pneumothorax. The FLCN gene is believed to function as a tumor suppressor gene. Therefore, patients with BHDS are predisposed to renal neoplasms, which are caused by the “second-hit” mutation on the wild-type FLCN allele. Earlier studies suggested that the mutated folliculin protein may retain partial functionality or show dominant negative effects and therefore contribute to clinical manifestations of BHDS (Hasumi et al., 2017; Luijten et al., 2013). Here we report a case with BHDS whose germline FLCN mutation was predicted to result in no protein synthesis and yet who developed all three manifestations of BHDS, facial papules, lung cysts, and chromophobe renal cell carcinoma (RCC). Additionally, the analysis of “second hit” in RCC suggested a complete lack of folliculin with no mutant protein.
Section snippets
Clinical report
A 38-year-old man of Russian descent was referred to our hospital for a left renal tumor. He had flesh-colored papules on his face (Fig. 1A). Laboratory tests revealed mild anemia (hemoglobin 12.5 g/dL), elevated lactase dehydrogenase (440 IU/L), and elevated C-reactive protein (2.74 mg/dL). Urinary cytology showed no malignant cells. Enhanced computed tomography (CT) revealed a heterogeneously-enhancing solid mass in the upper pole of his left kidney which was 70 mm in size (Fig. 1B). No lymph
Histopathologic and immunohistochemical examinations
The patient's resected renal tissues were fixed in 10% buffered formalin, embedded in paraffin after routine processing, and stained with hematoxylin and eosin (H&E). Immunostaining was performed with antibodies directed to folliculin (dilution 1:150, Santa Cruz, Paso Robles, CA, USA). 3, 3′-diaminobenzidine tetrahydrochloride (dilution 1:200, Abcam, Cambridge, UK). Fast Red (Nichirei Bioscience Inc., Tokyo, Japan) was used as the chromogen.
Mutation analysis of the FLCN gene
Genomic DNA isolated from peripheral blood leukocytes
Results
A FLCN genetic test was performed for the patient and his family members, which confirmed the diagnosis of BHDS (Fig. 2, Fig. 3A). The mutation of the FLCN gene we identified in the proband (II-3 in Fig. 2) was a large genomic deletion including FCLN exon 1, which segregated in the affected sister and her asymptomatic children (II-2, III-1, and III-2 in Fig. 2). The proband's father did not undergo genetic testing (I-1 in Fig. 2). This genomic deletion has already been submitted to ClinVar by
Discussion
The FLCN gene, encoding folliculin protein, consists of 14 exons; the coding sequence is included in exons 4 to 14 (Nickerson et al., 2002). Earlier studies demonstrated that patients with BHDS had various germline FLCN mutations, most of which contain frameshift, nonsense or splice site mutations and are expected to generate truncated and presumably inactivated form of folliculin (Lim et al., 2010; Vocke et al., 2005). Less frequently, large intragenic deletions or duplications and FLCN
Consent
Written informed consent was obtained from the patient to publish this case report, including any accompanying images. A copy of the written consent is available upon request.
Authors' contributions
YE drafted the manuscript and provided the medical care. YN and KS helped draft the manuscript. YH, KM, EK, and KS performed the molecular genetic studies and immunohistochemical analyses. YK provided medical care and helped creat some figures. HK provided the medical care and participated in the study design and coordination. YM and TU provided histopathological diagnosis and prepared the microphotographs of renal tumor. YH conceived of the study and helped draft the manuscript. All authors
Declaration of competing interest
The authors declare that there is no conflict of interests regarding the publication of this study.
Acknowledgements
We thank Ms. Elaine Blumberg for her excellent proofreading and editing of English.
References (22)
- et al.
Identification and characterization of a novel folliculin-interacting protein FNIP2
Gene
(2008) - et al.
Mutations in a novel gene lead to kidney tumors, lung wall defects, and benign tumors of the hair follicle in patients with the Birt-Hogg-Dubé syndrome
Cancer Cell
(2002) - et al.
The folliculin tumor suppressor is a GAP for the RagC/D GTPases that signal amino acid levels to mTORC1
Mol. Cell
(2013) - et al.
Folliculin encoded by the BHD gene interacts with a binding protein, FNIP1, and AMPK, and is involved in AMPK and mTOR signaling
Proc. Natl. Acad. Sci.
(2006) - et al.
Identification of intragenic deletions and duplication in the FLCN gene in Birt-Hogg-Dubé syndrome
Genes Chromosomes Cancer
(2011) - et al.
Protein misfolding and degradation in genetic diseases
Hum. Mutat.
(1999) - et al.
Novel mutations in the folliculin gene associated with spontaneous pneumothorax
Eur. Respir. J.
(2008) - et al.
Protein misfolding and cellular stress: an overview
Methods Mol. Biol.
(2010) - et al.
Mutations of the Birt-Hogg-Dubé gene in patients with multiple lung cysts and recurrent pneumothorax
J. Med. Genet.
(2007) - et al.
H255Y and K508R missense mutations in tumour suppressor folliculin (FLCN) promote kidney cell proliferation
Hum. Mol. Genet.
(2017)
Homozygous loss of BHD causes early embryonic lethality and kidney tumor development with activation of mTORC1 and mTORC2
Proc. Natl. Acad. Sci.
Cited by (4)
A systematic review assessing the existence of pneumothorax-only variants of FLCN. Implications for lifelong surveillance of renal tumours
2021, European Journal of Human GeneticsA Novel FLCN Intragenic Deletion Identified by NGS in a BHDS Family and Literature Review
2021, Frontiers in GeneticsLymphoplasmacytic lymphoma in a patient with Birt–Hogg–Dubé syndrome
2020, International Journal of Hematology